<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Tosi A</submitter><funding>Università degli Studi di Padova</funding><funding>Fidia Farmaceutici</funding><pagination>109</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11005197</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>43(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The intravesical instillation of the paclitaxel-hyaluronan conjugate ONCOFID-P-B™ in patients with bacillus Calmette-Guérin (BCG)-unresponsive bladder carcinoma in situ (CIS; NCT04798703 phase I study), induced 75 and 40% of complete response (CR) after 12 weeks of intensive phase and 12 months of maintenance phase, respectively. The aim of this study was to provide a detailed description of the tumor microenvironment (TME) of ONCOFID-P-B™-treated BCG-unresponsive bladder CIS patients enrolled in the NCT04798703 phase I study, in order to identify predictive biomarkers of response.&lt;h4>Methods&lt;/h4>The composition and spatial interactions of tumor-infiltrating immune cells and the expression of the most relevant hyaluronic acid (HA) receptors on cancer cells, were analyzed</pubmed_abstract><journal>Journal of experimental &amp; clinical cancer research : CR</journal><pubmed_title>A paclitaxel-hyaluronan conjugate (ONCOFID-P-B™) in patients with BCG-unresponsive carcinoma in situ of the bladder: a dynamic assessment of the tumor microenvironment.</pubmed_title><pmcid>PMC11005197</pmcid><funding_grant_id>Specific grant to AR</funding_grant_id><pubmed_authors>Bortoluzzi S</pubmed_authors><pubmed_authors>Parisatto B</pubmed_authors><pubmed_authors>Gaffo E</pubmed_authors><pubmed_authors>Rosato A</pubmed_authors><pubmed_authors>Tosi A</pubmed_authors></additional><is_claimable>false</is_claimable><name>A paclitaxel-hyaluronan conjugate (ONCOFID-P-B™) in patients with BCG-unresponsive carcinoma in situ of the bladder: a dynamic assessment of the tumor microenvironment.</name><description>&lt;h4>Background&lt;/h4>The intravesical instillation of the paclitaxel-hyaluronan conjugate ONCOFID-P-B™ in patients with bacillus Calmette-Guérin (BCG)-unresponsive bladder carcinoma in situ (CIS; NCT04798703 phase I study), induced 75 and 40% of complete response (CR) after 12 weeks of intensive phase and 12 months of maintenance phase, respectively. The aim of this study was to provide a detailed description of the tumor microenvironment (TME) of ONCOFID-P-B™-treated BCG-unresponsive bladder CIS patients enrolled in the NCT04798703 phase I study, in order to identify predictive biomarkers of response.&lt;h4>Methods&lt;/h4>The composition and spatial interactions of tumor-infiltrating immune cells and the expression of the most relevant hyaluronic acid (HA) receptors on cancer cells, were analyzed</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Apr</publication><modification>2026-06-01T23:36:07.114Z</modification><creation>2024-11-13T18:32:00.677Z</creation></dates><accession>S-EPMC11005197</accession><cross_references><pubmed>38600583</pubmed><doi>10.1186/s13046-024-03028-5</doi></cross_references></HashMap>